Wordt geladen...
New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous system, and both T and B cells are involved in its pathogenesis. The vast majority of disease-modifying drugs used for MS act on the inflammatory component of the disease and are approved for use in relap...
Bewaard in:
| Gepubliceerd in: | Neuropsychiatr Dis Treat |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5922247/ https://ncbi.nlm.nih.gov/pubmed/29719400 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/NDT.S147874 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|